Ozivy: Anvisa aprova 1º concorrente nacional da semaglutida após fim da patente da Novo Nordisk

from Saúde · host CBN

A Agência Nacional de Vigilância Sanitária (Anvisa) aprovou o registro do Ozivy, medicamento à base de semaglutida fabricado pela EMS, maior laboratório farmacêutico do Brasil. Learn more about your ad choices. Visit megaphone.fm/adchoices

What this episode covers

NOW PLAYING

0:00 3:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Saúde?

This episode is 3 minutes long.

When was this Saúde episode published?

This episode was published on May 26, 2026.

What is this episode about?

Can I download this Saúde episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!